Dr. Aimin Xu

Degrees
Bachelor of Clinical Medicine, Anhui Medical University, China
PhD, University of Auckland, New Zealand
Current position
Professor, Dept of Medicine & Department of Pharmacology, The University of Hong Kong

Appointments
Academic Editor, Biochemical Journal
Academic Editor, PLOS One
Editorial board member, Cardiovascular Drugs and Therapy
Editorial board, Clinical Science
Visiting Professor, Guangzhou Institute of Biomedicine & Health, Chinese Academy of Sciences
Visiting Professor, Xiangya Medical School, Central South University

Consulting experience
Servier

Biography
Dr Aimin Xu trained in medicine at Anhui University followed by a postdoctoral training at University of Auckland before appointment at University of Hong Kong. Dr Xu’s research is dedicated to delineate the molecular basis that links obesity with diabetes and cardiovascular disease, with particular focuses on adipokines released from fat tissue. His team is one of the word leading groups in the field of adiponectin, a major fat-derived insulin-sensitizing adipokine with anti-diabetic, anti-atherosclerotic and anti-inflammatory properties. His research work contributed substantially to the understanding of the molecular structure, signaling pathways and physiological functions of adiponectin. Dr Xu’s laboratory has initiated a series of applied research project aiming to develop novel diagnostic tools and therapeutics for risk prediction, treatment and prevention of diabetic and vascular complications. They also established an integrated platform for high throughput drug screening and validation of drug target in animal models. He holds several patents as inventor.